Effects of Table Tennis for People With Parkinson's Disease

May 30, 2024 updated by: Helena Fernández-Lago, Universitat de Lleida

Motor and Cognitive Effects of Table Tennis on Parkinson's Disease: Pilot Controlled Trial

Quasi-experimental, controlled, non-randomised two-arm pilot, with an experimental group (table tennis exercise) and an active control group (cognitive training based on board games).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Quasi-experimental, controlled, non-randomised two-arm pilot, with an experimental group (table tennis exercise) and an active control group (cognitive training based on board games). Interventions in both groups will take place twice a week for 6 weeks (12 sessions in total). The main variables to be assessed will be motor and cognitive. As secondary variables, clinical and daily life aspects will be assessed. As results, it is expected that the experimental group will obtain improvements in motor variables compared to the control group after receiving the interventions. However, improvements in cognitive variables and secondary variables are expected to be similar in both groups.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of Parkinson's Disease based on the UK PD Society Brain Bank Criteria
  • Stage I to III on the Hoehn and Yahr scale
  • Ability to walk for 10 minutes unassisted

Exclusion Criteria:

  • Score of under 23 on the Mini-Mental State Examination
  • Severe Visual or Auditory deficits
  • Cardiovascular conditions that impede physical activity
  • Brain surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Table Tennis
Participants will follow supervised Table Tennis sessions lasting 60 minutes during 6 weeks, for a total of 12 sessions.
Other: Exercise and cognitive training interventino
Exercise and cognitive training based on Table tennis and Tabletop games.
Experimental: Tabletop Games
Participants will follow supervised Tabletop Game sessions lasting 60 minutes during 6 weeks, for a total of 12 sessions.
Other: Exercise and cognitive training interventino
Exercise and cognitive training based on Table tennis and Tabletop games.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Amplitude of Center of Pressure under simple conditions
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of amplitude of Center of Pressure (in mm) during balance testing using OPAL Sensors (APDM, Oregon, USA).
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Amplitude of Center of Pressure under Dual Task conditions (Motor)
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of amplitude of Center of Pressure (in mm) during balance testing under concurrent cognitive tasks (Motor, by holding a glass of water on a tray) using OPAL Sensors (APDM, Oregon, USA).
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Amplitude of Center of Pressure under Dual Task conditions (Arithmetic)
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of amplitude of Center of Pressure (in mm) during balance testing under concurrent cognitive tasks (Arithmetic, by concurrently substracting 7 from a random number) using OPAL Sensors (APDM, Oregon, USA).
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Amplitude of Center of Pressure under Dual Task conditions (Verbal)
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of amplitude of Center of Pressure (in mm) during balance testing under concurrent cognitive tasks (Verbal, by naming words starting by a random letter) using OPAL Sensors (APDM, Oregon, USA).
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Trail-Making Test
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of Trail-Making Test parts A and B
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
United Parkinson's Disease Rating Scale - Part III
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of Motor symptoms of Parkinson's Disease with a predetermined assessment
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Montreal Cognitive Assessment
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of cognitive status to detect Mild Cognitive Impairment with a preset questionnaire.
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Parkinson's Disease Questionnaire - 8
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of Quality of Life for people with Parkinson's Disease through a self-administered questionnaire
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Timed Up and Go test
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of gait mobility and fall risk by getting up from a chair, walking 3 meters, turning back and sitting again.
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Falls Efficacy Scale International
Time Frame: Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).
Assessment of perceived fall risk with a predetermined questionnaire.
Assessed before starting the intervention (T0) and 6 weeks later (T0 + 6 weeks).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Universitat de Lleida

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Club Tennis Taula Borges Blanques
Asociació de Parkinson de les Terres de Lleida

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 12, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 30, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 5, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 5, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 30, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2023CRINDESTABC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings